MICaB Graduate Program
Main navigation |
Masato Yamamoto, M.D., Ph.D.
Division of Basic and Translational Research, Department of Surgery
Osaka University, M.D. 1988; Ph.D. 1997
office - 612-624-9131
Cancer gene-therapy and virotherapy
Our goal is to develop clinically usable gene-/viro-therapy modalities for solid tumors, e.g. GI cancers including pancreatic cancer. Our group has been developing cancer therapeutics with adenovirus as gene delivery tool. Current gene therapy modalities for cancer have not achieved the expected therapeutic efficiency due to disease related obstacles. Our lab is developing advanced version of adenovirus vectors and oncolytic adenoviruses by employing virological advance. We perform extensive vector engineering and produce the viruses/vectors to overcome the issues impeding clinical realization of this kind of therapeutics. Recent advances include 1) Development of adenovirus targeting ligand library and its application to the targeted delivery upon systemic administration, 2) Theranostics enables tumor imaging and tumor selective radiotherapy employing sodium-iodine symporter, 3) Combination viro-therapy with INF-alpha expressing oncolytic adenovirus and chemoradiation, 4) Development of cancer stem cell targeted oncolytic adenovirus.
Selected Recent Publications:
- Miura Y, Yamasaki S, Davydova J, Brown E, Aoki K, Vickers SM, and Yamamoto M. Infectivity-Selective Oncolytic Adenovirus Developed by High-throughput Screening of Adenovirus-formatted Library. Molecular Therapy. 2012. (Pubmed ahead of print)
- Yamamoto M, Curiel DT. 2010. Current Issues and Future Directions of Oncolytic Adenoviruses. Mol Ther. Feb;18(2):243-50.
- Li HJ, Everts M, Yamamoto M, Curiel DT, and Herschman HR. 2009. Combined transductional untargeting/retargeting and transcriptional restriction enhance adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res. Jan 15;69(2):554-64.
- Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S, Curiel DT, Yamamoto M. 2006. Dynamic Monitoring of Oncolytic Adenovirus In Vivo by Genetic Capsid Labeling. J Natl Cancer Inst. Feb 1;98(3):203-14.
- Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M .2005. Non-invasive Visualization of Adenovirus Replication with a Fluorescent Reporter in the E3 Region. Cancer Res. Nov 15;65(22):10154-8.
- Davydova J, Le LP, Gavrokova T, Wang M, Krasnykh V, Yamamoto M .2004. Infectivity-enhanced Cyclooxygenase-2-based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma. Cancer Research. Jul 15:64(12):4319-27.
- Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM and Curiel DT. 2003. Infectivity Enhanced, Cyclooxygenase-2 Promoter-Based Conditionally Replicative Adenovirus for Pancreatic Cancer. Gastroenterology. October; 125(4):1203-1218.